12:00 AM
 | 
Feb 16, 2015
 |  BC Week In Review  |  Company News  |  Deals

ActoGeniX, Intrexon deal

Synthetic biology company Intrexon will acquire ActoGeniX for $60 million, comprising $30 million in cash and $30 million in stock. Intrexon will gain ActoGeniX’s TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms....

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >